Saturday 17 October 2026
Export DXCM’s income statement to Excel — free account
DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
86.06
1.65
−1.88%
Follow DXCM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
36.37 | 30.87 | 26.17 | 26.00 |
P/S ratio |
5.83 | 5.56 | 5.02 | 5.18 | |
P/FCF ratio |
24.78 | 24.04 | 16.92 | 18.32 | |
P/Operating CF |
39.88 | 88.09 | 46.01 | 95.62 | |
P/B ratio |
9.65 | 9.43 | 8.18 | 9.82 | |
Price to Tangible BV |
10.03 | 9.77 | 8.43 | 10.31 | |
EV/Sales |
5.54 | 5.56 | 4.94 | 5.19 | |
EV/EBITDA |
24.47 | 22.27 | 18.40 | 18.39 | |
EV/Operating CF |
17.27 | 17.99 | 13.34 | 14.76 | |
EV/FCF |
23.55 | 24.06 | 16.64 | 18.37 | |
Quick Ratio |
1.33 | 1.50 | 1.58 | 1.36 | |
Current Ratio |
1.56 | 1.88 | 1.95 | 1.73 | |
Net Debt/EBITDA |
(6.80) | (1.95) | (3.64) | (1.82) | |
Debt/Assets |
16.53% | 19.57% | 18.72% | 19.25% | |
Debt/Equity |
0.45 | 0.45 | 0.42 | 0.47 | |
Asset Turnover |
0.65 | 0.73 | 0.72 | 0.72 | |
Operating CF/Net income |
2.33 | 1.10 | 2.63 | 1.08 | |
Capex/Depreciation |
(1.27) | (1.56) | (1.14) | (1.24) | |
Research and Development Expense of Revenue |
13.02% | 11.77% | 12.19% | 11.69% | |
Selling, General and Administrative Expense of Revenue |
27.40% | 25.52% | 29.34% | 27.42% | |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.01 | 0.02 | |
Share Based Compensation of Revenue |
3.73% | 2.78% | 3.63% | 2.98% | |
Graham Net Nets |
0.02 | 0.02 | 0.03 | 0.01 | |
Graham Number |
17.03 | 18.45 | 20.36 | 19.99 | |
Earnings Yield |
2.75% | 3.24% | 3.82% | 3.85% | |
Free Cash Flow Yield |
4.04% | 4.16% | 5.91% | 5.46% | |
Revenue per Share |
3.09 | 3.23 | 3.10 | 3.42 | |
Operating CF per Share |
1.69 | 0.75 | 1.36 | 0.70 | |
Capex per Share |
(0.21) | (0.26) | (0.20) | (0.22) | |
Free Cash Flow per Share |
1.48 | 0.49 | 1.17 | 0.48 | |
Cash per Share |
8.49 | 5.12 | 6.27 | 5.09 | |
Shareholders Equity per Share |
6.97 | 7.04 | 7.68 | 6.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.97 | 7.04 | 7.68 | 6.86 | |
Free Cash Flow |
579.40 | 192.10 | 449.00 | 184.50 | |
Working Capital |
1,883.50 | 1,890.80 | 2,107.90 | 1,728.90 | |
Capital Expenditures |
(80.50) | (101.90) | (76.60) | (84.70) | |
Net Current Asset Value |
445.60 | 439.40 | 655.30 | 252.70 | |
EV/EBIT |
32.16 | 28.42 | 23.01 | 22.66 | |
Capex to Sales |
0.07 | 0.08 | 0.06 | 0.06 | |
Price to Operating Income |
33.84 | 28.40 | 23.40 | 22.60 | |
| Other line items | |||||
Average Receivables |
1,055.80 | 1,110.90 | 1,121.90 | 1,303.25 | |
Average Payables |
1,762.45 | 1,764.55 | 1,882.25 | 2,067.65 | |
Average Inventory |
595.20 | 585.85 | 615.90 | 648.55 | |
Average Assets |
6,926.90 | 6,412.20 | 6,692.50 | 6,891.15 | |
Average Common Equity |
2,352.55 | 2,424.30 | 2,611.75 | 2,597.25 |
Columns are period end dates